Patent intelligence · EP
EP 3630112
KOMBINATION AUS REGORAFENIB UND PD-1/PD-L1(2)-INHIBITOREN ZUR BEHANDLUNG VON KREBS
KOMBINATION AUS REGORAFENIB UND PD-1/PD-L1(2)-INHIBITOREN ZUR BEHANDLUNG VON KREBS
Patent details — EP 3630112
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Apr 8, 2020
- Expiration
- Apr 3, 2040
- Applicant
- BAYER AG [DE]
- CPC classes
- A61K 31/ 44 A I, A61K 31/ 395 A I, A61K 45/ 06 A I, A61K/31395
Quick answer
EP 3630112 (KOMBINATION AUS REGORAFENIB UND PD-1/PD-L1(2)-INHIBITOREN ZUR BEHANDLUNG VON KREBS) is held by BAYER AG [DE]. Status: granted. Granted Apr 8, 2020. Expires Apr 3, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BAYER AG [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 44 A I, A61K 31/ 395 A I, A61K 45/ 06 A I, A61K/31395, A61K/3144, A61K/314412
Frequently asked questions
What is US patent 3630112?
EP 3630112 (KOMBINATION AUS REGORAFENIB UND PD-1/PD-L1(2)-INHIBITOREN ZUR BEHANDLUNG VON KREBS) is held by BAYER AG [DE]. Status: granted. Granted Apr 8, 2020. Expires Apr 3, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 3630112?
BAYER AG [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does EP 3630112 expire?
Our index shows an expiration date of Apr 3, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.